PHILADELPHIA--(BUSINESS WIRE)--Feb. 15, 2006--
The Alfa Laval Biokinetics office in Philadelphia, PA has just completed the design and construction of a prototype production module for high-quality, cell free DNA. The module has been constructed on behalf of Houston-based company, CytoGenix, Inc.
The prototype module, capable of producing gram quantities in a single pass in 24 hours, will serve as the core piece of equipment for CytoGenix' proprietary, high-throughput DNA GMP manufacturing facility.
Alfa Laval engineers and CytoGenix scientists worked closely to design and produce a remarkably simple yet highly efficient module. The compact nature of the design and the closed-loop architecture of the system will facilitate ease of production in virtually any GMP production facility.
Jennifer DeBerardinis, US Account Manager for Alfa Laval Biokinetics, commented, "Alfa Laval is excited to be at the forefront of this breakthrough in technology for DNA manufacture. This module represents a fundamental improvement to the science of making clinical grade DNA. We look forward to continued design and engineering projects with CytoGenix as they expand their DNA manufacturing capabilities."
Kurt Berens, CytoGenix, Inc. Vice President of Product Development, commented, "CytoGenix is delighted at the rapidity with which the project was completed and the responsiveness of the design team at Alfa Laval. The design, fabrication and time to delivery were exemplary by industry standards and speak to the efficiency and experience of the Alfa Laval team. We will begin scale-up and validation of the manufacturing process using this production module and additional modules will be added to meet the growing demand for clinical-grade DNA to support our product development programs and to accommodate the commercial market for synDNA™."
About CytoGenix: CytoGenix, Inc. (CYGX.OB) is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA _expression technology.
CytoGenix currently has one issued US patent and 41 international or US pending patent applications claiming methods and materials in connection with this platform technology. CytoGenix has recently filed a US Patent Application for synDNA™ Vaccines and Other Therapeutic Compounds.
About Alfa Laval: Alfa Laval is a leading global provider of specialized products and engineering solutions based on its key technologies of heat transfer, separation and fluid handling.
The company's equipment, systems and services are dedicated to assisting customers in optimizing the performance of their processes. The solutions help them to heat, cool, separate and transport products in industries that produce food and beverages, chemicals and petrochemicals, pharmaceuticals, starch, sugar and ethanol. Alfa Laval's products are also used in power plants, aboard ships, in the mechanical engineering industry, in the mining industry and for wastewater treatment, as well as for comfort climate and refrigeration applications.
Alfa Laval's worldwide organization works closely with customers in nearly 100 countries to help them stay ahead in the global arena.
Alfa Laval is listed on the Stockholm Exchange and, in 2004, posted annual sales of about SEK 15 billion (approx. 1.7 billion euros). The company has some 9,500 employees.
For further information, please visit the Alfa Laval website at www.alfalaval.com.
CONTACT: Alfa Laval Biokinetics
Jennifer DeBerardinis, 215-656-2515
jennifer.deberardinis@alfalaval.com
or
CytoGenix, Inc.
Juan Ferreira, 800-677-5707
or
Alfa Laval Copenhagen A/S, Denmark
Tom Thane Nielsen, +45 39 53 64 85
tomthane.nielsen@alfalaval.com
SOURCE: Alfa Laval
Copyright Business Wire 2006
